Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases
Location: United Kingdom
Employees: 11-50
Total raised: $5.09M
Founded date: 2023
Investors 2
| Date | Name | Website |
| 04.07.2025 | Ono Ventur... | onoventure... |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.11.2023 | - | $5.09M | - |
Mentions in press and media 11
| Date | Title | Description |
| 16.02.2026 | Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board | Cambridge, UK, 16 February 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces the nomination of HRN001 as its le... |
| 30.10.2025 | Ono Venture Investment made a strategic additional funding for research collaboration with Harness. (Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Ve... | - |
| 06.10.2025 | Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment | Cambridge, UK, 06 October 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces the establishment of the second gen... |
| 25.02.2025 | Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference | Cambridge, UK, 25 February 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces that it will present a poster on t... |
| 27.01.2025 | Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline | Cambridge, UK, 27 January 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces it has appointed Dr Heather Preston... |
| 04.09.2024 | Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director | Cambridge, UK, September 4, 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop disease-modifying therapeutics for neurodegenerative diseases, today announces the appointment of Dr Paulo Fontoura t... |
| 30.05.2024 | Harness Therapeutics appoints Leading World Experts in Neurodegenerative Diseases to its Scientific Advisory Board (SAB) | Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK, May 30, 2024: Harness Therapeutics, a biotechnology company... |
| 30.11.2023 | Harness Therapeutics Raises Additional £4M in Funding | Harness Therapeutics, a Cambridge, UK-based biotechnology company focused on physiological protein upregulation, raised additional £4M in funding. The round brought the total amount to £17.6M. Backers included SV Health Investors, investing... |
| 28.11.2023 | Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases | Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics), a biotechnology company focused on physiological protein upregulation to develop next generation therapeutics for the treatment of neurod... |
| 28.11.2023 | Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases | - |
Show more